Nitric oxide (NO) holds promise as a cytotoxic agent against tumors, but its gaseous nature and short half-life hinder direct administration to tumor tissues. Herein, we present novel 6,9-disubstituted purine derivatives designed to ensure sustained NO release, followed by study of their significant anti-proliferative, anti-migratory, and anti-clonogenic effects on HepG2 cell lines, highlighting NO release as a potent effector for treating hepatocellular carcinoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/d4cc00232f | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!